Methods of treating chemoresistance and relapse in cancer cells
Methods of treating or preventing chemoresistance or relapse growth of cancer cells are provided. Methods of treating or preventing resistance to tyrosine kinase based chemotherapeutic treatment in hematologic and solid tumors are provided. BCR-ABL drug resistance in chronic myelogenous leukemia (CML) and models for conducting further study on the same are presented. The methods comprise administering a therapeutically effective amount of one or more SIRT 1 modulators to the cells or subject in need thereof. The methods may be administered in combination with, prior to or subsequent to chemotherapy or may be administered to counteract the effect of a spontaneous genetic mutation. Methods of using SIRT 1 inhibitors to treat or prevent insulin and transferrin-induced resistance are also presented. A novel cell model to study mechanisms of acquired chemoresistance is also provided.
1. A method for treating cell resistance to chemotherapy or reducing relapse growth of a chronic myelogenous leukemia (CML) cancer cell comprising administering a therapeutically effective amount of a SIRT1 inhibitor and a therapeutically effective amount of one or more tyrosine kinase inhibitors selected from the group consisting of STI-571, imatinib, nilotinib, and VS-680 to the cell, wherein the SIRT1 inhibitor is sirtinol, splitomicin, nicotinamide, shRNA Sh1, shRNA Sh2, or a combination thereof, and wherein said administration results in reduced cell resistance to chemotherapy or reduced relapse growth of the CML cancer cell.
2. The method of claim 1 , wherein the SIRT1 inhibitor is administered for the purpose of preventing the formation of one or more BCR-ABL mutations in the cell.
3. The method of claim 2 , wherein if the tyrosine kinase inhibitor is imatinib or STI-571, the one or more BCR-ABL mutations are selected from the group consisting of T315I, E255K, and Y253H.
4. The method of claim 1 , wherein the SIRT1 inhibitor is administered at or about the same time as the administration of the tyrosine kinase inhibitor.
5. The method of claim 1 , wherein the SIRT1 inhibitor is administered prior to or subsequent to the administration of the tyrosine kinase inhibitor.
6. The method of claim 2 , wherein the one or more tyrosine kinase inhibitors are imatinib and VX-680 or STI-571 and VX-680.
7. The method of claim 6 , wherein the one or more BCR-ABL mutations is T315I.